Return to homepagePandemic Pact

STUDY OF THE PROTECTION OF BCG AND MTBVAC AGAINST SARS-Cov-2 IN PRIMATES

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00820

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Carlos Martín Montañés

  • Research Location

    Spain

  • Lead Research Institution

    UNIVERSIDAD DE ZARAGOZA

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Study of the prophylactic activity of the trained innate immunity induced by the live attenuated vaccine MTBVAC compared with BCG against SARS-CoV2 in the model of rhesus macaques (Macaca mulatta) at the Biomedical Primate Research Center (BPRC) in the Netherlands. The present investigation is part of the studies that the BPRC is going to begin on the protective activity due to the increase of the trained immunity induced by BCG against SARS-CoV2, studying the inoculation of the BCG vaccine by different routes of administration (intradermal, pulmonary and intravenous) and which co-finances this proposal at 50%.